Alpine Immune Sciences, Inc. (ALPN)
Alpine Immune Sciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Seattle, WA, US. The stock last traded at $64.97, up 0.02% on the session, giving a market capitalisation of $4.46B. On trailing twelve-month figures it carries a trailing P/E of -101.52, a net margin of -54.7%. Its beta of 0.97 implies it has historically moved less than the broad market.
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Alpine Immune Sciences, Inc. is most often compared with the following Healthcare names: